Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

Item

http://www.wikidata.org/entity/Q36825817

Q36825817

about

Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

Item

http://www.wikidata.org/entity/Q36825817

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pathological complete response ...... y and review of the literature

@en

type

Item

label

Pathological complete response ...... y and review of the literature

@en

prefLabel

Pathological complete response ...... y and review of the literature

@en

P1476

Pathological complete response ...... y and review of the literature

@en

P2093

Fumi Masumoto

http://www.w3.org/2001/XMLSchema#string

Hirotoshi Takahashi

http://www.w3.org/2001/XMLSchema#string

Hiroyasu Yamashiro

http://www.w3.org/2001/XMLSchema#string

Misao Atsumi

http://www.w3.org/2001/XMLSchema#string

Nao Morii

http://www.w3.org/2001/XMLSchema#string

Shinji Ozaki

http://www.w3.org/2001/XMLSchema#string

Takayoshi Kiba

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Inflammatory breast cancer: a review.

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?

P304

3064-3070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2016.4334

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

298734693

http://www.w3.org/2001/XMLSchema#string

P698

27123064

http://www.w3.org/2001/XMLSchema#string

P932

4841046

http://www.w3.org/2001/XMLSchema#string

Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

about

Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932